JPMorgan Chase & Co. Buys 67,325 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

JPMorgan Chase & Co. boosted its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 221.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 97,660 shares of the company's stock after purchasing an additional 67,325 shares during the quarter. JPMorgan Chase & Co. owned about 0.22% of Y-mAbs Therapeutics worth $765,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC increased its position in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company's stock valued at $910,000 after buying an additional 56,244 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock valued at $10,699,000 after acquiring an additional 47,846 shares in the last quarter. AlphaQuest LLC increased its holdings in shares of Y-mAbs Therapeutics by 6,911.6% during the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company's stock valued at $212,000 after acquiring an additional 26,748 shares in the last quarter. Principal Financial Group Inc. bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $267,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Y-mAbs Therapeutics during the 4th quarter valued at about $46,000. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ:YMAB traded up $0.30 during midday trading on Friday, hitting $4.41. The company had a trading volume of 163,173 shares, compared to its average volume of 326,063. Y-mAbs Therapeutics, Inc. has a 12-month low of $3.84 and a 12-month high of $17.47. The company has a fifty day moving average of $4.70 and a two-hundred day moving average of $7.79. The company has a market cap of $199.67 million, a price-to-earnings ratio of -8.17 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $26.50 million during the quarter, compared to analysts' expectations of $26.70 million. During the same quarter in the previous year, the company earned ($0.02) EPS. Research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 22.50% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on YMAB shares. HC Wainwright dropped their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Wedbush reaffirmed an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a research note on Tuesday, April 22nd. Finally, Truist Financial reduced their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.40.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.